Lonza Group Ag Debt to Equity Ratio 2012-2025 | LZAGY
Current and historical debt to equity ratio values for Lonza Group Ag (LZAGY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Lonza Group Ag debt/equity for the three months ending June 30, 2025 was 0.42.
| Lonza Group Ag Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-06-30 | $12.28B | $10.52B | 1.17 |
| 2024-12-31 | $11.75B | $10.66B | 1.10 |
| 2024-06-30 | $9.37B | $10.41B | 0.90 |
| 2023-12-31 | $8.17B | $10.60B | 0.77 |
| 2023-06-30 | $8.12B | $11.54B | 0.70 |
| 2022-12-31 | $7.01B | $11.18B | 0.63 |
| 2022-06-30 | $6.89B | $10.45B | 0.66 |
| 2021-12-31 | $7.26B | $10.75B | 0.68 |
| 2021-06-30 | $8.59B | $8.06B | 1.07 |
| 2020-12-31 | $8.05B | $7.34B | 1.10 |
| 2020-06-30 | $7.69B | $6.79B | 1.13 |
| 2019-12-31 | $7.32B | $6.61B | 1.11 |
| 2019-06-30 | $7.23B | $6.23B | 1.16 |
| 2018-12-31 | $7.80B | $6.43B | 1.21 |
| 2018-06-30 | $7.71B | $6.50B | 1.19 |
| 2017-12-31 | $7.66B | $6.36B | 1.21 |
| 2017-06-30 | $4.35B | $5.39B | 0.81 |
| 2016-12-31 | $4.54B | $2.39B | 1.90 |
| 2016-06-30 | $4.37B | $2.12B | 2.07 |
| 2015-12-31 | $4.28B | $2.22B | 1.93 |
| 2015-06-30 | $4.34B | $2.08B | 2.09 |
| 2014-12-31 | $4.72B | $2.33B | 2.02 |
| 2014-06-30 | $5.09B | $2.34B | 2.18 |
| 2013-12-31 | $4.77B | $2.30B | 2.08 |
| 2013-06-30 | $5.15B | $2.28B | 2.26 |
| 2012-12-31 | $5.01B | $2.57B | 1.95 |
| 2012-06-30 | $4.99B | $2.52B | 1.98 |
| 2011-12-31 | $5.28B | $2.67B | 1.98 |
| 2011-06-30 | $2.60B | $2.46B | 1.06 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $46.091B | $7.881B |
| Lonza Group AG operates as a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The company's Life Science Ingredients segment produces nutrition ingredients for applications in nutrition (food, feed and pharmaceutical application) and chemical intermediates for the agricultural industry. The Microbial Control division focuses on five areas: hygiene, wood protection, water treatment, oil/gas applications, and industrial preservation and comprises products ranging from disinfectants to household cleaning products. The Custom Manufacturing division comprises products used in pharmaceuticals sector. The Bioscience division comprises bioscience products, including cell culture and molecular biology tools for research, tests for microbial detection, and media used in the production of therapeutics. Lonza Group AG is headquartered in Basel, Switzerland. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $197.518B | 22.06 |
| EssilorLuxottica (ESLOY) | France | $154.739B | 0.00 |
| Stryker (SYK) | United States | $139.087B | 26.68 |
| Medtronic (MDT) | Ireland | $129.586B | 17.95 |
| Boston Scientific (BSX) | United States | $108.915B | 24.09 |
| Medline (MDLN) | United States | $59.170B | 0.00 |
| ResMed (RMD) | United States | $37.821B | 25.25 |
| Agilent Technologies (A) | United States | $36.458B | 23.10 |
| GE HealthCare Technologies (GEHC) | United States | $36.095B | 17.29 |
| Koninklijke Philips (PHG) | Netherlands | $30.881B | 18.33 |
| Terumo (TRUMY) | Japan | $20.046B | 22.65 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.948B | 11.66 |
| Insulet (PODD) | United States | $17.647B | 54.77 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.998B | 0.00 |
| Baxter (BAX) | United States | $11.448B | 9.24 |
| Sunny Optical Technology (SNPTF) | China | $8.485B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.922B | 28.49 |
| Demant (WILYY) | Denmark | $6.264B | 0.00 |
| Envista Holdings (NVST) | United States | $4.976B | 25.22 |
| Lantheus Holdings (LNTH) | United States | $4.461B | 13.59 |
| BillionToOne (BLLN) | United States | $3.924B | 0.00 |
| ICU Medical (ICUI) | United States | $3.647B | 23.16 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.263B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.122B | 14.73 |
| Haemonetics (HAE) | United States | $2.672B | 11.69 |
| Neogen (NEOG) | United States | $2.338B | 51.19 |
| Phibro Animal Health (PAHC) | United States | $2.088B | 18.40 |
| Perrigo (PRGO) | Ireland | $2.009B | 5.03 |
| LeMaitre Vascular (LMAT) | United States | $1.991B | 40.08 |
| QuidelOrtho (QDEL) | United States | $1.956B | 13.59 |
| Curaleaf Holdings (CURLF) | Canada | $1.649B | 0.00 |
| AtriCure (ATRC) | United States | $1.635B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $1.625B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.427B | 20.67 |
| Green Thumb Industries (GTBIF) | United States | $1.390B | 60.91 |
| Lumexa Imaging Holdings (LMRI) | United States | $1.304B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $1.106B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.071B | 317.86 |
| InMode (INMD) | Israel | $0.902B | 9.89 |
| Tilray Brands (TLRY) | Canada | $0.888B | 0.00 |
| Valneva SE (VALN) | France | $0.834B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.798B | 0.00 |
| Omeros (OMER) | United States | $0.796B | 0.00 |
| CeriBell (CBLL) | United States | $0.763B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.570B | 13.61 |
| Brainsway (BWAY) | Israel | $0.459B | 78.10 |
| Verano Holdings (VRNO) | United States | $0.432B | 0.00 |
| Cerus (CERS) | United States | $0.413B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.394B | 0.00 |
| SNDL (SNDL) | Canada | $0.386B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.361B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.328B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.321B | 25.61 |
| Quanterix (QTRX) | United States | $0.279B | 0.00 |
| Evolus (EOLS) | United States | $0.279B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.240B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Sanuwave Health (SNWV) | United States | $0.212B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.206B | 18.45 |
| High Tide (HITI) | Canada | $0.205B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.202B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.195B | 57.33 |
| TerrAscend (TSNDF) | Canada | $0.188B | 0.00 |
| Accendra Health (ACH) | United States | $0.184B | 1.85 |
| Organigram Global (OGI) | Canada | $0.177B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.176B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.174B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| Apyx Medical (APYX) | United States | $0.150B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.133B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.129B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.74 |
| MacroGenics (MGNX) | United States | $0.109B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.098B | 0.00 |
| Biote (BTMD) | United States | $0.097B | 4.24 |
| Exagen (XGN) | United States | $0.075B | 0.00 |
| ImmuCell (ICCC) | United States | $0.059B | 24.96 |
| Sharps Technology (STSS) | United States | $0.048B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.043B | 0.00 |
| Nephros (NEPH) | United States | $0.043B | 31.08 |
| Cytosorbents (CTSO) | United States | $0.039B | 0.00 |
| Veru (VERU) | United States | $0.037B | 0.00 |
| Modular Medical (MODD) | United States | $0.035B | 0.00 |
| United-Guardian (UG) | United States | $0.030B | 15.40 |
| Jin Medical (ZJYL) | China | $0.025B | 0.00 |
| Bonk (BNKK) | United States | $0.020B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.014B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| INLIF (INLF) | China | $0.009B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.007B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Functional Brands (MEHA) | United States | $0.004B | 0.00 |
| Agape ATP (ATPC) | $0.003B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |